0001209191-19-004571.txt : 20190118
0001209191-19-004571.hdr.sgml : 20190118
20190118165135
ACCESSION NUMBER: 0001209191-19-004571
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20190116
FILED AS OF DATE: 20190118
DATE AS OF CHANGE: 20190118
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: HILZINGER KURT J
CENTRAL INDEX KEY: 0001191504
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-37759
FILM NUMBER: 19533663
MAIL ADDRESS:
STREET 1: 1300 MORRIS DRIVE
STREET 2: SUITE 100
CITY: CHESTERBROOK
STATE: PA
ZIP: 19087
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Outlook Therapeutics, Inc.
CENTRAL INDEX KEY: 0001649989
STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
IRS NUMBER: 383982704
STATE OF INCORPORATION: DE
FISCAL YEAR END: 0930
BUSINESS ADDRESS:
STREET 1: 7 CLARKE DRIVE
CITY: CRANBURY
STATE: NJ
ZIP: 08512
BUSINESS PHONE: 6096193990
MAIL ADDRESS:
STREET 1: 7 CLARKE DRIVE
CITY: CRANBURY
STATE: NJ
ZIP: 08512
FORMER COMPANY:
FORMER CONFORMED NAME: Oncobiologics, Inc.
DATE OF NAME CHANGE: 20150804
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2019-01-16
0
0001649989
Outlook Therapeutics, Inc.
OTLK
0001191504
HILZINGER KURT J
C/O OUTLOOK THERAPEUTICS, INC.
7 CLARKE DRIVE
CRANBURY
NJ
08512
1
0
0
0
Common Stock
2019-01-16
4
P
0
800
0.68
A
112147
D
Common Stock
2019-01-17
4
P
0
2300
0.69
A
114447
D
The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $0.68 - $0.687, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote to this Form 4.
The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $0.67 - $0.69, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote to this Form 4.
/s/ Lawrence A. Kenyon, Attorney-in-Fact
2019-01-18